[A20-48] Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2020
Project no.:
A20-48
Commission:
Commission awarded on 29.05.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
| Adults with BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer |
Result of dossier assessment:
| Hint of considerable added benefit |
| Project no. | Title | Status |
|---|---|---|
| A20-89 | Talazoparib (breast cancer) - Addendum to Commission A20-48 | Commission completed |
| A24-22 | Talazoparib (prostate cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
20.11.2020 A G-BA decision was published.